POAI Predictive Oncology Inc
Price (delayed)
$0.9
Market cap
$6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.35
Enterprise value
$3.37M
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data
Highlights
The EPS has increased by 32% YoY and by 8% from the previous quarter
POAI's net income is up by 27% year-on-year and by 5% since the previous quarter
POAI's gross profit is down by 16% since the previous quarter but it is up by 4.5% year-on-year
POAI's revenue is up by 13% YoY but it is down by 11% from the previous quarter
Predictive Oncology's equity has shrunk by 72% YoY
Predictive Oncology's quick ratio has shrunk by 69% YoY
Key stats
What are the main financial stats of POAI
Market
Valuations
Earnings
Shares outstanding
6.67M
Market cap
$6M
Enterprise value
$3.37M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.9
Price to sales (P/S)
2.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.93
Revenue
$1.75M
EBIT
-$14.04M
EBITDA
-$13.39M
Free cash flow
-$12.83M
Per share
Balance sheet
Liquidity
EPS
-$3.35
Free cash flow per share
-$2.75
Book value per share
$1
Revenue per share
$0.37
TBVPS
$2.22
Total assets
$10.59M
Total liabilities
$6.49M
Debt
$2.7M
Equity
$4.09M
Working capital
$2.27M
Debt to equity
0.66
Current ratio
1.49
Quick ratio
1.24
Net debt/EBITDA
0.2
Margins
Efficiency
Dividend
EBITDA margin
-765.9%
Gross margin
60.2%
Net margin
-802.9%
Operating margin
-809.5%
Return on assets
-104.4%
Return on equity
-200.1%
Return on invested capital
-358.4%
Return on capital employed
-235.2%
Return on sales
-802.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
POAI stock price
How has the Predictive Oncology stock price performed over time
Intraday
2.39%
1 week
-1.64%
1 month
-9.13%
1 year
-73.29%
YTD
-72.64%
QTD
-13.46%
Financial performance
How have Predictive Oncology's revenue and profit performed over time
Revenue
$1.75M
Gross profit
$1.05M
Operating income
-$14.15M
Net income
-$14.04M
Gross margin
60.2%
Net margin
-802.9%
The company's net margin rose by 36% YoY but it fell by 6% QoQ
POAI's operating margin is up by 36% year-on-year but it is down by 6% since the previous quarter
POAI's net income is up by 27% year-on-year and by 5% since the previous quarter
POAI's operating income is up by 27% YoY and by 5% QoQ
Growth
What is Predictive Oncology's growth rate over time
Valuation
What is Predictive Oncology stock price valuation
P/E
N/A
P/B
0.9
P/S
2.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.93
The EPS has increased by 32% YoY and by 8% from the previous quarter
Predictive Oncology's equity has shrunk by 72% YoY
The price to book (P/B) is 44% less than the last 4 quarters average of 1.6 and 40% less than the 5-year quarterly average of 1.5
The P/S is 88% lower than the 5-year quarterly average of 19.6 and 58% lower than the last 4 quarters average of 5.7
POAI's revenue is up by 13% YoY but it is down by 11% from the previous quarter
Efficiency
How efficient is Predictive Oncology business performance
The company's return on equity has shrunk by 119% YoY and by 31% QoQ
Predictive Oncology's ROIC has increased by 49% YoY but it has decreased by 7% from the previous quarter
The return on assets has declined by 42% year-on-year and by 13% since the previous quarter
The ROS has increased by 36% YoY but it has decreased by 6% from the previous quarter
Dividends
What is POAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for POAI.
Financial health
How did Predictive Oncology financials performed over time
The company's total assets is 63% higher than its total liabilities
Predictive Oncology's quick ratio has shrunk by 69% YoY
The current ratio has dropped by 65% year-on-year but it has increased by 2.8% since the previous quarter
The company's debt is 34% lower than its equity
Predictive Oncology's equity has shrunk by 72% YoY
The company's debt fell by 9% YoY but it rose by 3.6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.